Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The S-adenosylmethionine-I (SAM-I) riboswitch is a highly conserved regulatory RNA element found in the 5' untranslated regions of various bacterial mRNAs (Winkler et al., 2003, Nature). It functions as a molecular sensor that directly binds S-adenosylmethionine, the primary methyl donor in cellular metabolism (Montange & Batey, 2006, Nature). Upon binding its ligand, the riboswitch undergoes a structural rearrangement that typically suppresses the expression of genes involved in methionine and SAM biosynthesis. This regulation occurs through mechanisms such as the formation of a transcription terminator hairpin or the sequestration of the ribosome binding site (Blount & Breaker, 2006, Nature Biotechnology). Because these riboswitches are essential for bacterial fitness and are not found in humans, they are considered attractive targets for the development of novel antimicrobial agents. Small molecule analogs of SAM can be designed to bind the riboswitch and constitutively repress vital metabolic pathways, leading to bacterial growth inhibition (Lünse et al., 2014, ChemBioChem). Current research explores these mimetics as potential treatments for infections caused by Gram-positive pathogens. However, challenges remain regarding the specificity of these compounds and the potential for bacteria to develop resistance through mutations in the RNA structure.
Ligand binding to the aptamer domain induces a conformational change in the expression platform, leading to transcriptional termination or translational inhibition of downstream metabolic genes (Winkler et al., 2003, Nature).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-adenosylmethionine-I riboswitch (SAM-I riboswitch) (SAM-I riboswitch).